Form 4: Atara Biotherapeutics Executive Jill Henrich Sells Shares to Cover Tax Obligations

Jill Henrich, EVP and Chief Regulatory Officer at Atara Biotherapeutics, sold 1,000 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Jill Henrich, an executive at Atara Biotherapeutics, sold 1,000 shares of the company's common stock on November 18, 2024.
• The sale was executed at a price of $11.198 per share.
• This transaction was to cover tax withholding obligations associated with the vesting of previously granted restricted stock units.
• Following the transaction, Ms. Henrich directly owns 19,378 shares of Atara Biotherapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the biotechnology industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar tax-related sales by executives.
• The sale of 1,000 shares is not unusual for an executive at a company of Atara's size.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but it is generally considered a routine transaction.

Key Dates

Keywords

Atara Biotherapeutics, insider trading, stock sale, executive, Jill Henrich, tax obligations, restricted stock units